Thymalin vs Thymosin Alpha-1

Thymalin wins for:

• Long-term mortality impact with cyclic, pulsed protocols (especially in longevity and post-blast immune-reset scenarios).
• Deep thymic restoration, including normalization of CD4/CD8 profiles and general immune homeostasis.
• Extensive published clinical data from Eastern-European cohorts spanning decades.
• Structured use: short, infrequent courses versus daily or chronic administration.

Thymosin Alpha-1 wins for:

• Ongoing immune support during long, suppressive PED protocols — more flexible as a standing adjunct during AAS/GH/insulin cycles.
• Broader clinical use worldwide (Zadaxin), with strong data in viral recovery, ICU settings, and on-cycle protection.
• Established safety in prolonged and repeat administration protocols.
• Clean side-effect profile with lower risk of immune flare or allergy versus animal-derived extracts.

Pick Thymalin if:

• The protocol mirrors Khavinson's pulsed, annual or semiannual thymic reset (especially in a geroprotective or longevity-focused stack).
• The priority is post-cycle immune normalization after long AAS/GH use, using short, well-tolerated courses.
• Deep thymic reactivation and restoration of immune-age markers (CD4/CD8 correction, IL-6 suppression) is the main goal.
• Preference is for classic Russian protocols with heavy published backing.
• Willing to source animal-derived peptides and manage possible bovine-protein sensitivities.

Pick Thymosin Alpha-1 if:

• The goal is continuous or as-needed immune support during extended PED cycles or post-viral syndromes.
• Flexibility and ease of protocol (1.6 mg 2x/week, or higher during acute phases) is a top priority.
• Preference for a synthetic, single-sequence peptide with very low allergy risk and easy sourcing.
• Proactive insurance against overtraining, illness susceptibility, or immunosenescence.
• Avoiding animal extracts due to sensitivities or sourcing concerns.